Sakar Healthcare Limited (SAKAR.NS)
INR 258.29
(6.94%)
INR 258.29
(6.94%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 699.58 Million INR | 16.96% |
| 2022 | 598.12 Million INR | 11.98% |
| 2021 | 534.12 Million INR | 23.51% |
| 2020 | 432.45 Million INR | 10.37% |
| 2019 | 391.81 Million INR | 20.36% |
| 2018 | 325.55 Million INR | 31.31% |
| 2017 | 247.92 Million INR | 13.28% |
| 2016 | 218.85 Million INR | 13.64% |
| 2015 | 192.58 Million INR | 8.84% |
| 2014 | 176.94 Million INR | 7.52% |
| 2013 | 164.57 Million INR | 22.39% |
| 2012 | 134.46 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 93.06 Million INR | 7.66% |
| 2024 Q1 | 86.44 Million INR | 6.98% |
| 2023 Q1 | 178.18 Million INR | -1.98% |
| 2023 Q2 | 172.14 Million INR | -3.39% |
| 2023 FY | 282.92 Million INR | -52.7% |
| 2023 Q4 | 80.8 Million INR | 7.0% |
| 2023 Q3 | 75.51 Million INR | -56.13% |
| 2022 Q2 | 136.41 Million INR | 8.39% |
| 2022 Q4 | 181.78 Million INR | 17.98% |
| 2022 FY | 598.12 Million INR | 11.98% |
| 2022 Q1 | 125.85 Million INR | -21.06% |
| 2022 Q3 | 154.07 Million INR | 12.95% |
| 2021 Q2 | 119.95 Million INR | -6.47% |
| 2021 Q1 | 128.25 Million INR | 2.41% |
| 2021 FY | 534.12 Million INR | 23.51% |
| 2021 Q4 | 159.43 Million INR | 26.05% |
| 2021 Q3 | 126.48 Million INR | 5.45% |
| 2020 Q1 | 94.6 Million INR | 3.8% |
| 2020 FY | 432.45 Million INR | 10.37% |
| 2020 Q4 | 125.23 Million INR | 38.15% |
| 2020 Q3 | 90.65 Million INR | -25.68% |
| 2020 Q2 | 121.96 Million INR | 28.92% |
| 2019 Q3 | 98.1 Million INR | -18.34% |
| 2019 Q1 | 82.44 Million INR | -13.85% |
| 2019 FY | 391.81 Million INR | 20.36% |
| 2019 Q2 | 120.13 Million INR | 45.7% |
| 2019 Q4 | 91.13 Million INR | -7.09% |
| 2018 Q3 | 99 Million INR | 30.57% |
| 2018 Q4 | 95.69 Million INR | -3.34% |
| 2018 FY | 325.55 Million INR | 31.31% |
| 2018 Q1 | 55.01 Million INR | 0.0% |
| 2018 Q2 | 75.83 Million INR | 37.84% |
| 2017 FY | 247.92 Million INR | 13.28% |
| 2016 FY | 218.85 Million INR | 13.64% |
| 2016 Q4 | 119.57 Million INR | 0.0% |
| 2015 Q2 | 54.45 Million INR | 0.0% |
| 2015 Q3 | 42.75 Million INR | -21.49% |
| 2015 Q4 | 103.77 Million INR | 142.73% |
| 2015 FY | 192.58 Million INR | 8.84% |
| 2015 Q1 | 54.45 Million INR | 51.31% |
| 2014 FY | 176.94 Million INR | 7.52% |
| 2014 Q4 | 35.99 Million INR | 0.0% |
| 2013 FY | 164.57 Million INR | 22.39% |
| 2012 FY | 134.46 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 97.388% |
| Hester Biosciences Limited | 1.27 Billion INR | 45.072% |
| Aarti Drugs Limited | 8.31 Billion INR | 91.588% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 88.003% |
| Albert David Limited | 1.4 Billion INR | 50.317% |
| Alembic Limited | 1 Billion INR | 30.049% |
| Alkem Laboratories Limited | 52.29 Billion INR | 98.662% |
| Bafna Pharmaceuticals Limited | 452.15 Million INR | -54.723% |
| Bajaj HealthCare Limited | 1.47 Billion INR | 52.468% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.54 Million INR | -5476.604% |
| Brooks Laboratories Limited | 65.62 Million INR | -966.116% |
| Eris Lifesciences Limited | 10.42 Billion INR | 93.291% |
| FDC Limited | 6.58 Billion INR | 89.378% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 94.373% |
| Gufic Biosciences Limited | 4.07 Billion INR | 82.827% |
| Hikal Limited | 5.95 Billion INR | 88.258% |
| Ind-Swift Limited | 2.17 Billion INR | 67.799% |
| Innova Captab Limited | 3.46 Billion INR | 79.807% |
| IOL Chemicals and Pharmaceuticals Limited | 4.71 Billion INR | 85.175% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -7.201% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 96.439% |
| Lincoln Pharmaceuticals Limited | 1.88 Billion INR | 62.923% |
| Lupin Limited | 125.09 Billion INR | 99.441% |
| Mangalam Drugs & Organics Limited | 691.19 Million INR | -1.214% |
| Medico Remedies Limited | 262.14 Million INR | -166.87% |
| Morepen Laboratories Limited | 6.16 Billion INR | 88.645% |
| Nectar Lifesciences Limited | 4.82 Billion INR | 85.496% |
| Orchid Pharma Limited | 2.32 Billion INR | 69.849% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 87.899% |
| RPG Life Sciences Limited | 2.48 Billion INR | 71.825% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -12.75% |
| Sigachi Industries Limited | 2 Billion INR | 65.061% |
| Solara Active Pharma Sciences Limited | -1.65 Billion INR | 142.248% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | 83.033% |
| Themis Medicare Limited | 2.42 Billion INR | 71.092% |
| Unichem Laboratories Limited | 4.86 Billion INR | 85.62% |
| Vaishali Pharma Limited | 90.32 Million INR | -674.537% |
| Wanbury Limited | 1.73 Billion INR | 59.577% |
| Windlas Biotech Limited | 1.33 Billion INR | 47.745% |
| ZIM Laboratories Limited | 1.26 Billion INR | 44.82% |
| Ind-Swift Laboratories Limited | 4.13 Billion INR | 83.074% |
| Ipca Laboratories Limited | 48.58 Billion INR | 98.56% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 99.729% |
| Venus Remedies Limited | 2.18 Billion INR | 67.947% |
| Aurobindo Pharma Limited | 109.54 Billion INR | 99.361% |
| Divi's Laboratories Limited | 32.44 Billion INR | 97.843% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 88.758% |
| Mankind Pharma Limited | 42.19 Billion INR | 98.342% |
| Sequent Scientific Limited | 2.97 Billion INR | 76.514% |
| Laurus Labs Limited | 15.44 Billion INR | 95.472% |
| Neuland Laboratories Limited | 8.24 Billion INR | 91.518% |
| J. B. Chemicals & Pharmaceuticals Limited | 15.25 Billion INR | 95.415% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 98.991% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 99.441% |
| Amrutanjan Health Care Limited | 2.09 Billion INR | 66.592% |
| Wockhardt Limited | 7.72 Billion INR | 90.938% |
| Bal Pharma Limited | 770.19 Million INR | 9.168% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 99.572% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | 81.069% |
| Par Drugs and Chemicals Limited | 529.13 Million INR | -32.213% |
| Caplin Point Laboratories Limited | 9.2 Billion INR | 92.401% |
| Shilpa Medicare Limited | 3.56 Billion INR | 80.359% |
| Valiant Laboratories Limited | 138.02 Million INR | -406.839% |
| Ajanta Pharma Limited | 21.06 Billion INR | 96.679% |
| Aarey Drugs & Pharmaceuticals Limited | 113.02 Million INR | -518.943% |
| Granules India Limited | 16.79 Billion INR | 95.836% |
| Medicamen Biotech Limited | 495.49 Million INR | -41.189% |
| Syncom Formulations (India) Limited | 559.5 Million INR | -25.037% |
| Piramal Enterprises Limited | 8.04 Billion INR | 91.302% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 98.504% |
| NATCO Pharma Limited | 25.73 Billion INR | 97.282% |
| Suven Life Sciences Limited | -200.79 Million INR | 448.404% |
| Krebs Biochemicals & Industries Limited | -108.74 Million INR | 743.314% |
| Strides Pharma Science Limited | 14.38 Billion INR | 95.138% |
| Indoco Remedies Limited | 8.04 Billion INR | 91.302% |
| Alpa Laboratories Limited | 188.89 Million INR | -270.357% |
| Lasa Supergenerics Limited | 121.02 Million INR | -478.026% |
| Sun Pharma Advanced Research Company Limited | 391.06 Million INR | -78.892% |